Has Jose Nieto, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,946 in general payments to Jose Nieto, MD across 173 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jose Nieto, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jose Nieto, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jose Nieto, MD

Nephrology · Miami, FLNPI 1811950132

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.2% of the total across 173 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations.

$3,946in general payments, 2019–2025

Across 173 payments — averaging $22.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Mallinckrodt Hospital Products Inc.$628
AstraZeneca$577
Amgen$421
Vifor Pharma, Inc.$375
Bayer$344
Aurinia Pharma U.S., Inc.$236
plus $1K from 18 others

$61,261in research payments, 2019–2025

Across 21 payments — averaging $2917.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

GSK$60K
Ironwood Pharmaceuticals, Inc$1K

What the payments were for

Food & beverage$3,87398%
Education$732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Mallinckrodt Hospital Products Inc.	28	$628
AstraZeneca	29	$577
Amgen(2 entities)	21	$421
Vifor Pharma, Inc.	17	$375
Bayer	13	$344
Aurinia Pharma U.S., Inc.	11	$236
Novartis	9	$218
Fresenius USA Marketing, Inc.	9	$185
Calliditas Therapeutics US Inc.	6	$135
Pentax Of America, Inc.	1	$129
ANI Pharmaceuticals, Inc.	4	$126
Travere Therapeutics, Inc.	4	$89
Novo Nordisk	4	$75
Mallinckrodt Enterprises LLC	2	$61
Takeda Pharmaceuticals U.S.A., Inc.	2	$61
OPKO Pharmaceuticals, LLC	3	$61
Olympus America Inc.	1	$49
Boehringer Ingelheim	2	$41
Ardelyx, Inc.	2	$32
GSK	1	$28
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$25
Shire North American Group Inc	1	$21
Otsuka America Pharmaceutical, Inc.	1	$19
Pinnacle Biologics, Inc	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

C2 Cryoballoon$129

How this compares

$3,946 in reported general payments places this provider in the 75th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida →

Medicare billing

Part B allowed, 2024

$258,330

Medicare patients

243

Services billed

2,372

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Sevelamer Carbonate	14	$953
Nifedipine ErNifedipine	49	$943
Calcium Acetate	20	$681
Lactulose	11	$407
Furosemide	39	$196
Clonidine Hcl	12	$172
Losartan Potassium	15	$144
Allopurinol	17	$136
Ciprofloxacin Hcl	15	$130
Lisinopril	20	$118
Amlodipine Besylate	18	$24

Paid to pharmacies, not to this prescriber.

Other nephrology in Miami

Gabriel ContrerasMiami$133K
Alessia FornoniMiami$97K
Jonathan da CostaMiami$74K
Yelena DrexlerMiami$43K
Jochen ReiserMiami$43K
Alba Gonzalez-OchoaMiami$39K
Jorge BusseMiami$28K
Loay SalmanMiami$14K
David RothMiami$12K
Arvind MadanOrlando$943K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →